Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | EEF2K | O00418 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343134 | 0.82 | KMT2A (0.53) | KMT2ATLR9ATMKDM4ELMNA | |
| SCHEMBL1770021 | 0.82 | KMT2A (0.53) | KMT2ATLR9ATMKDM4ELMNA | |
| SCHEMBL18083006 | 0.81 | KDM4E (0.58) | KMT2AKDM4ESMN1; SMN2MEN1MAPT | |
| SCHEMBL20043208 | 0.80 | KDM4E (0.40) | KMT2AKDM4ESMN1; SMN2MEN1KCNH2 | |
| SCHEMBL20043227 | 0.80 | KDM4E (0.40) | KMT2AKDM4ESMN1; SMN2MEN1KCNH2 | |
| SCHEMBL14427995 | 0.77 | ALDH1A1 (0.52) | KDM4EMAPTALDH1A1HSD17B10GAA | |
| SCHEMBL4586206 | 0.73 | KMT2A (0.67) | KMT2ATLR9ATMKDM4ELMNA | |
| SCHEMBL29922808 | 0.73 | KMT2A (0.67) | KMT2ATLR9ATMKDM4ELMNA | |
| SCHEMBL3480837 | 0.73 | KMT2A (0.67) | KMT2ATLR9ATMKDM4ELMNA | |
| SCHEMBL31087686 | 0.71 | KMT2A (0.61) | KMT2ATLR9ATMKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2691377-B1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) | 2018-03-07 | — | — | EP | disclosed |
| EP-2691377-B1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) | 2018-03-07 | — | — | EP | disclosed |
| US-9434701-B2 | Aminoquinoxaline derivatives for treatment of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-06 | — | — | US | disclosed |
| US-9434701-B2 | Aminoquinoxaline derivatives for treatment of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-06 | — | — | US | disclosed |
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| WO-2012131080-A1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-10-04 | — | — | WO | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | KMT2A 2351/4885TLR9 2905/4885ATM 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.